Literature DB >> 25904124

Ocular manifestations in systemic lupus erythematosus.

Sukhum Silpa-archa1, Joan J Lee2, C Stephen Foster3.   

Abstract

Systemic lupus erythematosus (SLE) can involve many parts of the eye, including the eyelid, ocular adnexa, sclera, cornea, uvea, retina and optic nerve. Ocular manifestations of SLE are common and may lead to permanent blindness from the underlying disease or therapeutic side effects. Keratoconjunctivitis sicca is the most common manifestation. However, vision loss may result from involvement of the retina, choroid and optic nerve. Ocular symptoms are correlated to systemic disease activity and can present as an initial manifestation of SLE. The established treatment includes prompt systemic corticosteroids, steroid-sparing immunosuppressive drugs and biological agents. Local ocular therapies are options with promising efficacy. The early recognition of disease and treatment provides reduction of visual morbidity and mortality. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Choroid; Immunology; Inflammation; Optic Nerve; Retina

Mesh:

Substances:

Year:  2015        PMID: 25904124     DOI: 10.1136/bjophthalmol-2015-306629

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  34 in total

1.  Alterations in biomechanical properties of the cornea among patients with polycystic kidney disease.

Authors:  Kubra Serefoglu Cabuk; Bennur Esen; Kursat Atalay; Ahmet Kirgiz; Rukiye Aydin
Journal:  Int Ophthalmol       Date:  2017-06-29       Impact factor: 2.031

2.  Retinal thickness and microvascular alterations in the diagnosis of systemic lupus erythematosus: a new approach.

Authors:  Ren Liu; Yan Wang; Qiang Xia; Tian Xu; Ting Han; Shuang Cai; Shui-Lin Luo; Rui Wu; Yi Shao
Journal:  Quant Imaging Med Surg       Date:  2022-01

3.  The incidence, risk factor, and time to develop rheumatologic diseases after isolated inflammatory eye diseases: a 12-year cohort study.

Authors:  Kittiwan Sumethkul; Indhira Urailert; Tassanee Kitumnuaypong; Sungchai Angthararak; Sukhum Silpa-Archa
Journal:  Clin Rheumatol       Date:  2022-01-10       Impact factor: 2.980

Review 4.  [Ocular involvement in rheumatoid arthritis, connective tissue diseases and vasculitis].

Authors:  I Kötter; N Stübiger; C Deuter
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

Review 5.  Orbital compartment syndrome as the first manifestation of SLE.

Authors:  Maria Colon; Lara El Khoury
Journal:  Clin Rheumatol       Date:  2020-03-09       Impact factor: 2.980

6.  Evaluation of subclinical retinopathy and angiopathy with OCT and OCTA in patients with systemic lupus erythematosus.

Authors:  Mehmed Uğur Işık; Berkay Akmaz; Fahrettin Akay; Yusuf Ziya Güven; Dilek Solmaz; Önay Gercik; Gökhan Kabadayı; İdil Kurut; Servet Akar
Journal:  Int Ophthalmol       Date:  2020-08-26       Impact factor: 2.031

Review 7.  Systemic lupus erythematosus and ocular involvement: an overview.

Authors:  Rosanna Dammacco
Journal:  Clin Exp Med       Date:  2017-12-14       Impact factor: 3.984

Review 8.  Ocular manifestations of rheumatic diseases.

Authors:  Adam Kemeny-Beke; Peter Szodoray
Journal:  Int Ophthalmol       Date:  2019-10-03       Impact factor: 2.031

Review 9.  Plasmacytoid dendritic cells in the eye.

Authors:  Arsia Jamali; Brendan Kenyon; Gustavo Ortiz; Abdo Abou-Slaybi; Victor G Sendra; Deshea L Harris; Pedram Hamrah
Journal:  Prog Retin Eye Res       Date:  2020-07-24       Impact factor: 21.198

Review 10.  Immunogenetics of the Ocular Anterior Segment: Lessons from Inherited Disorders.

Authors:  Jasmine Y Serpen; Stephen T Armenti; Lev Prasov
Journal:  J Ophthalmol       Date:  2021-06-28       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.